Searchable abstracts of presentations at key conferences in endocrinology

ea0025p289 | Steroids | SFEBES2011

Glucocorticoid receptor antagonism as a decision making tool in patients with adrenal incidentaloma and low-grade excess cortisol secretion: a pilot study

Debono Miguel , Houghton Sam , Eastell Richard , Ross Richard , Newell-Price John

Aims/hypothesis: Adrenal incidentaloma (AI) are very common, but optimal management of patients with AI and low-grade excess cortisol secretion is not established. Uncontrolled studies reporting outcomes of adrenalectomy suggest improvements in cardiovascular risk, but all are subject to selection bias, and it is unclear if benefits are due to removal of excess cortisol. We reasoned that short-term use of mifepristone, a rapidly-acting glucocorticoid receptor (GR) antagonist, ...

ea0032en2.2 | (1) | ECE2013

Management of CAH in adults

Ross Richard

CAH is the commonest inborn endocrine disorder and associated with significant morbidity. The health status of CAH adult patients has recently been reported by the UK Congenital adrenal Hyperplasia Adult Study Executive, CaHASE (Arlt et al. JCEM 2010 95 5110–5121). Compared to the health survey for England, metabolic abnormalities were common in adult patients with CAH: obesity (41%), hypercholesterolemia (46%), insulin resistance (29%),...

ea0031s6.3 | Making the glucocorticoid clock run smoothly (Supported by Addison's Disease self-help group) | SFEBES2013

Diurnal cortisol delivery: a novel tool for adrenal insufficiency

Ross Richard

Cortisol is an essential stress hormone and replacement with oral hydrocortisone is lifesaving in patients with adrenal insufficiency. Cortisol has a diurnal rhythm regulated by the central body clock and this rhythm is a metabolic signal for peripheral tissue clocks. Loss of cortisol rhythmicity is associated with fatigue, depression and insulin resistance. A general principle in endocrinology is to replace hormones to replicate physiological concentrations; however the pharm...

ea0028pl8 | Clinical Endocrinology Trust Medal Lecture | SFEBES2012

Developing growth hormone agonists and antagonists for the clinic

Ross Richard

Growth hormone (GH) is a potent anabolic hormone; deficiency results in extreme short stature and excess in gigantism and acromegaly. It is just over 50 years since Raben first demonstrated the dramatic impact of GH replacement on linear growth in a young boy with pituitary infantilism. Since then milestones in GH research have included identification of the GH binding protein (1986), the crystal structure of GH (1987), cloning of the GH receptor (1987) and the discovery of a ...

ea0025mte5 | (1) | SFEBES2011

Late effects of cancer therapy

Ross Richard

One in eight hundred young adults is now a survivor of childhood cancer as a result of tremendous advances in cancer therapy. However, this success now brings with it the challenge that both the cancer and its therapy may have late effects. In a recent review of 10 397 young adult survivors, 62.3% had at least one chronic condition; 27.5% had a severe or life-threatening condition (grade 3 or 4). The adjusted relative risk of a chronic condition in a survivor, as compared with...

ea0020s9.4 | Addison's disease from genetics to clinical outcome | ECE2009

New ways of delivering glucocorticoids

Ross Richard

Replication of physiology is a basic tenet of endocrinology but this is rarely achieved. We developed a modified-release hydrocortisone to provide circadian cortisol. The adrenal glucocorticoid, cortisol, is an essential stress hormone and its secretion follows a distinct rhythm regulated by the central circadian oscillator in the suprachiasmatic nucleus. Circulating cortisol levels are low at sleep onset, rise between 0200 and 0400 h, peak within an hour of waking and then de...

ea0016s28.4 | GH: structure–function relationship | ECE2008

Trafficking and function of GHR and the role of GHBP

Ross Richard

GH acts through a cell surface receptor, GHR, which is a member of the type 1 cytokine receptor family. Cytokine receptors have a single trans-membrane domain and dimerisation is required to activate intra-cellular signalling pathways. In common with other cytokine receptors the extra-cellular domain of the GHR is proteolitically cleaved and circulates as a binding protein. Under physiological conditions GH is in part bound in the circulation and the complex with the binding p...

ea0013s71 | A successful research career | SFEBES2007

Making money out of research

Ross Richard

Knowledge transfer has now entered common parlance to describe the interaction between industry and universities. Knowledge transfer frequently involves exchange of money. It consists of many different activities which include teaching, consultancy, licensing patents, and spinning out companies. Many academics provide consultancy to industry and this has the attractive benefits of bringing money to the individual and bringing industry to the university. Consultancy is usually ...

ea0081p3 | Adrenal and Cardiovascular Endocrinology | ECE2022

Long-term cardiometabolic morbidity in young adults wWith classic 21-hydroxylase deficiency congenital adrenal hyperplasia

Righi Beatrice , Rashid Ali Salma , Bryce Jillian , Tolinson Jeremy , Bonfig Walter , Baronio Federico , Costa Eduardo C , Guaragna-Filho Guilherme , T'Sjoen Guy , Cools Martine , Markosyan Renata , A S S Bachega Tania , C Miranda Mirela , Iotova Violeta , Falhammar Henrik , Ceccato Filippo , Daniel Eleni , Auchus Richard , Ross Richard , Ahmed Faisal

Background: Congenital adrenal hyperplasia (CAH) and long-term glucocorticoid treatment may be associated with an increased risk of developing cardiometabolic sequelae such as abnormal glucose homeostasis, hyperlipidaemia, hypertension, cardiovascular (CV) disease, obesity and osteoporosis.Objectives: To study the current practice amongst expert centres for assessing cardiometabolic outcomes in adult patients with 21-hydroxylase CAH and to assess the pre...

ea0028pl8biog | Clinical Endocrinology Trust Medal Lecture | SFEBES2012

Clinical Endocrinology Trust Medal Lecture

JM Ross Richard

Richard JM Ross, Professor of Endocrinology, Faculty Academic Lead for Innovation and Head of Unit Diabetes, Endocrinology & Metabolism, University of Sheffield, UK AbstractRichard Ross trained in Medicine at The Royal London Hospital (1974–1979) and in Endocrinology at St Bartholomew's Hospital, London (1983–1988). He was appointed to Sheffield University in 1995 and is Professor of Endocrinology and He...